Last reviewed · How we verify
NCT03244657
Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy
Phase 4 trial testing conbercept ophthalmic injection （0.5mg） in Polypoid Choroidal Vasculopathy (PCV) in 200 participants. Status unknown.
31 October 2019
Quick facts
| Lead sponsor | Chengdu Kanghong Biotech Co., Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 25 April 2017 |
| Primary completion | 31 October 2019 |
| Estimated completion | 28 February 2020 |
| Sites | 30 locations across China |
Drugs / interventions tested
- conbercept ophthalmic injection （0.5mg） — full drug profile →
- conbercept ophthalmic injection （0.5mg） — full drug profile →
Conditions studied
- Polypoid Choroidal Vasculopathy (PCV) — all drugs for Polypoid Choroidal Vasculopathy (PCV) →
Sponsor
Chengdu Kanghong Biotech Co., Ltd. — full company profile →
Who can join
Adults 45 to 85, any sex, with Polypoid Choroidal Vasculopathy (PCV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore efficacy and safety of 0.5 mg conbercept ophthalmic injection for long-term treatment of polypoid choroidal vasculopathy (PCV) subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03244657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of conbercept ophthalmic injection （0.5mg）
Trials testing the same drug.
- NCT07144865 — Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab In · NA · completed
Other Chengdu Kanghong Biotech Co., Ltd. trials
Trials by the same sponsor.
- NCT06885645 — First-In-Human Study in Participants With Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT04990271 — A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Inject · Phase 2 · unknown
- NCT04555304 — Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Ther · Phase 2 · unknown
- NCT03630952 — Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) · Phase 3 · terminated
- NCT03577899 — Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03244657 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chengdu Kanghong Biotech Co., Ltd.
- Last refreshed: 9 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03244657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing